CAMBRIDGE

Cambridge University Press
978-0-521-76058-4 - Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Edited by Chad E. Beyer and Stephen M. Stahl
Index
More information

Index

5-HT. *See* serotonergic system; serotonin
5-HTT. *See* serotonin transporter
5-hydroxy-indole acetic acid (5-HIAA)
  levels in CSF of depressed patients, 13
acetylcholine (ACh) system
  target for treatment strategies, 20–1
addictive behavior, 18
adrenalin 2A receptor (ADRA2A) gene, 125
agomelatine, 5, 19, 29
α_2-adrenoceptors
  antidepressant targets, 19
amitriptyline, 14, 102
AMPA receptors
  antidepressant targets, 21
anhedonia, 30
  animal models, 31
  definition, 71
  objective laboratory measurement, 82–3
anhedonia as a depressive endophenotype, 71, 73–83
  biological plausibility, 75–6
  clinical plausibility, 73–5
  cosegregation, 82
  familial association, 80
  future research directions, 84–5
  heritability, 81–2
  objective laboratory measurement, 82–3
  role of anhedonia in depression, 83–4
  specificity, 76–8
  state-independence, 78–9
animal models of depression
  affective and cognitive disturbances, 52
  anhedonia, 31
  barriers to development of novel treatments, 39
  brain abnormalities in depression, 35–7
  challenges, 30
  chronic antidepressant treatment, 34
  chronic mild stress model, 33
  current models, 31–3
  forced swim test, 31–3
  forced swim test modifications, 34
  gender differences, 35
  genetically modified mouse models, 33
  in-vivo brain monitoring, 37–9
  limitations, 30, 39
  modeling depressive symptoms, 30–1
  Morris water maze test, 34
  need for novel models, 29–30
  novel animal models, 33–4
  novelty-induced hypophagia model, 34
  open space swim test, 34
  preclinical models in translational research, 46–7
  range of approaches, 31
  requirements and aims, 30–1
  stress response, 34–5
  tail suspension test, 31–3
  translational neuroimaging, 49–50
  withdrawal of drugs of abuse, 33
anticipation (genetic), 96
antidepressant metabolism
  effects of individual genetic variations, 122–3
antidepressant therapeutic targets
  effects of genetic variations in, 123–5
antidepressant treatment approaches
  combination and augmentation strategies, 3–4
  looking beyond monoamines, 7
  new formulations of old medications, 4–5
  staging of major depression, 4
  successive monotherapies, 3
  unmet therapeutic needs, 3
antidepressant treatment strategies, 15–23
  5-HT1A/1B receptor targets, 18
  5-HT2A/2C receptor targets, 18–19
  5-HT2C receptor blockers, 5
  5-HT3/5A/7 antagonism, 19
  acetylcholine (ACh) system, 20–1
  α_2-adrenoceptor targets, 19
  AMPA receptor modulators, 21
  atypical antipsychotics, 5
  DA/NE release stimulator (bupropion), 18
  dual 5-HT/NE reuptake inhibitors, 17
  GABA-related approaches, 21
  glutamate system, 21
  histamine H3 antagonist and SSRI, 19
  HPA axis-related treatment, 20
  neurokinin receptor antagonists, 20
  NMDA receptor antagonists, 21
  non-monoaminergic approaches, 23
  norepinephrine dopamine disinhibitors, 5
  novel agents with new targets, 7
  selective NE reuptake inhibitors, 16–17
  substance P as target, 20
  triple monoamine reuptake inhibitors, 17–18
  ultraselective serotonin reuptake inhibitor (escitalopram), 15–16

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-76058-4 - Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Edited by Chad E. Beyer and Stephen M. Stahl
Index
More information

antidepressants
  animal models of chronic treatment, 34
  discovery of tricyclic antidepressants (TCAs), 2
  early discoveries, 1–2
  effectiveness in major depression, 13
  efficacy of interventions, 28
  history of development, 28–9
  limitations of current medications, 121
  novel drug targets, 29
  proven efficacy in trials, 121
  time lag to take effect, 2, 29
apolipoprotein E epsilon4 gene, 125
aprepitant, 20, 29
atypical antipsychotics
  treatment of depression, 5

BDNF (brain-derived neurotrophic factor), 3
  functions, 58
  gene, 96, 125
  gene polymorphism, 58
Beck Depression Inventory (BDI), 77
benzodiazepines
  co-administration with SSRIs, 21
  for patients with depression, 21
beta 3 agonists, 23
beta adrenalin receptor (betaARs) gene, 125
biomarkers
  applications for neuroimaging techniques, 50
  cognitive deficits in mood disorders, 51–2
  cognitive impairment, 52
  disease biomarkers, 50, 56
  HPA axis dysfunction under stress, 57–8
  negative bias, 52
  neuroimaging of negative bias, 50–1
  patient selection and stratification, 55–6
  pharmacodynamic, 54–5
  pharmacogenomics, 56
  pharmacokinetic, 54–5
  placebo effect, 60
  preclinical animal models, 52
  presymptomatic diagnosis in surrogate populations, 56–7
  role of inflammation in depression, 58–9
  role of neurotrophins, 58
  surrogate biomarkers, 46
  target validation biomarkers, 52–3
  target–compound interaction, 54
  vascular depression, 59–60
bipolar disorder
  distinction from unipolar depression, 7
  DSM-IV-TR criteria, 45
  functional disorders, 45–6
bipolar II disorder, 7
blood–brain barrier (BBB), 55
BOLD (blood oxygen level-dependent) imaging, 49
brain imaging
  abnormalities in depression, 35–7
brain monitoring
  animal models of depression, 37–9
brain-derived neurotrophic factor. *See* BDNF
bupropion, 15, 17, 21
  catecholamine (DA/NE) release stimulator, 18
  hydrobromide salt formulation, 4

California Psychological Inventory, 81
Cambridge Neuropsychological Test Automated Battery (CANTAB), 52
candidate gene studies
  MDD, 93–4
catecholamine (DA/NE) release stimulator
  bupropion, 18
catechol-*O*-methyltransferase (COMT) gene, 125
cerebrovascular disease
  vascular depression, 59–60
chronic mild stress model (animals), 33
citalopram, 3, 14, 28, 58, 102
  comparison with escitalopram, 16
  pharmacology, 15
classification of mood disorders, 71
  endophenotypic approach, 71
  limitations of diagnostic criteria, 71
  See also DSM-IV
clomipramine, 35
cognitive deficits in mood disorders
  neuroimaging biomarkers, 51–2
cognitive impairment
  biomarkers, 52
  preclinical animal models, 52
Composite International Diagnostic Interview (CIDI), 120
copy-number variation (CNV)
  MDD risk studies, 95
corticotropin-releasing factor (CRF), 20
cortisol
  glucocorticoid receptor antagonists, 112–14
COX-2 inhibitors, 23
cytochrome P450 enzymes (CYPs)
  effects of individual genetic variations, 122–3

depression, 4
  clinical effectiveness of antidepressants, 13
  clinical symptoms, 30
  comorbidity, 29
  etiology, 29
  health consequences, 120
  hypotheses of, 30
  monoamine hypothesis, 2, 13–14, 30
  morbidity and mortality, 12
  neurotransmitter receptor sensitivity hypothesis, 2
  prevalence, 1, 12, 28, 120
  psychiatric comorbidity, 13
  staging, 4
  subtypes, 12–13
  See also bipolar disorder; major depressive disorder (MDD); unipolar depression.
depression endophenotypes. *See* anhedonia endophenotypes

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-76058-4 - Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Edited by Chad E. Beyer and Stephen M. Stahl
Index
More information

depressive disorders
  as a spectrum, 7
  diagnostic challenges, 7–11
desimipramine, 17
desipramine, 102, 123
desvenlafaxine, 5, 15, 103
dexamethasone suppression test (DST), 57
diagnosis
  difficulties with mood disorders, 7–11
  distinction between unipolar and bipolar depression, 7
  mood disorders as a spectrum, 7
DISC1 (Disrupted in Schizophrenia-1) gene, 96
disease biomarkers, 50, 56
DNA structural variation
  MDD risk studies, 95–6
dopamine (DA)
  DA/NE release stimulator (bupropion), 18
  monoamine hypothesis of depression, 2
dopamine D2, D3, D4 receptor (DRD2, DRD3, DRD4) genes, 125
dopamine transporter (DAT) blockade, 2
dopamine transporter (DAT1) gene, 125
dorsal raphe nucleus, 14
drug discovery and development. *See* translational neuroimaging; translational research
DSM-IV
  heterogeneity of clinical phenotypes, 71
DSM-IV-TR
  criteria for mood disorders, 45
dual 5-HT/NE reuptake inhibitors, 17
duloxetine, 15, 103
dysphoria, 30

endophenotypes
  anhedonia as a depressive endophenotype, 73–84
  biological plausibility, 72, 75–6
  clinical plausibility, 72, 73–5
  cosegregation, 72, 82
  criteria, 72–3
  definition, 71–2
  familial association, 72, 80
  future research directions, 84–5
  heritability, 72, 81–2
  in MDD, 97–8
  limitations of current classification systems, 71
  measurement, 72–3, 82–3
  neuroticism, 98
  specificity, 72, 76–8
  state-independence, 72, 78–9
  validation, 72–3
  value in psychiatric research, 71–2
  See also biomarkers.
endophenotypic approach, 71–2
environmental stress
  effects of, 57–8
epigenetics, 96–7
epigenomics, 96–7
escitalopram, 15–16
  clinical trials in depressed patients, 16
  comparison with citalopram, 16
  comparison with venlafaxine, 16
  pharmacology, 15
  safety, 16
  tolerability, 16
eszopiclone, 21
etiology of depression, 29

familiality studies
  MDD, 90–1
fatty acid amide hydrolase inhibitors, 23
fluoxetine, 2, 14, 17, 28, 34, 55, 58, 59, 60, 102, 103
fluvoxamine, 14, 28, 55, 58, 102
fMRI (functional MRI), 49
  characterization of mood disorders, 49
  use in drug discovery and development, 49
  use in preclinical animal models, 49–50
forced swim test
  animal model of depression, 31–3, 34

galanthamine, 21
gamma-aminobutyric acid (GABA)
  antidepressant target, 21
gender differences
  animal models of depression, 35
genetic association studies
  MDD, 93–5
genetic linkage studies
  MDD, 93
genetic variations
  enzymes which metabolize ADs, 122–3
  therapeutic targets of ADs, 123–5
genetically modified mice
  models of depression, 33
  transgenic models of mood disorders, 53–4
genomewide association studies (GWAS), 94–5
glucocorticoid receptor antagonists, 112–14
glutamate system
  antidepressant targets, 21
glutamatergic targets, 108–11
glutathione-S-transferase (GST) gene, 123
G-protein beta3-subunit (Gbeta3) gene, 125

Hamilton depression rating scale (HAM-D scale), 12–13
heritability studies
  MDD, 91–3
heterogeneity of clinical phenotypes, 71
heterogeneity within classification criteria, 71
histamine H3 antagonist and SSRI, 19
Huntington's disease (HD)
  association with MDD, 96
hydroxyl bupropion, 15
hypothalamic–pituitary–adrenal (HPA) axis, 7
  candidate genes for MDD risk, 94
  glucocorticoid receptor antagonists, 112–14
  melanocortin receptor antagonists, 115–16
  role in depression, 30
  role in mood disorders, 57–8
  role in the stress response, 112

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-76058-4 - Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Edited by Chad E. Beyer and Stephen M. Stahl
Index
More information

targets for drug development, 112–16
treatment target, 20
vasopressin receptor antagonists, 114–15

idazoxane, 19
imipramine, 17, 28, 35, 46, 102
Implicit Association Test (IAT), 79
improving treatments. *See* antidepressant treatment approaches
individualized medicine. *See* pharmacogenomics
inflammation
role in depression, 58–9
Investigational New Drug requirements, 54
iproniazid, 2, 46
isonazid, 2

ketamine, 21

L-5-methyl-tetrahydrofolate (MTHF), 7
lithium, 55, 58
LSD, 13–14
Lu 21004, 18, 19
Lu AA 24530, 19

major depression, 12–13
clinical effectiveness of antidepressants, 13
depression subtypes, 12–13
morbidity and mortality, 12
prevalence, 12
psychiatric comorbidity, 13
staging, 4
major depressive disorder (MDD)
adoption studies, 92–3
association with rare genetic variations, 96
candidate gene studies, 93–4
common gene hypothesis, 96
copy-number variation (CNV) studies, 95
disease burden, 70
DSM-IV-TR criteria, 45
endophenotypes, 97–8
familiality studies, 90–1
family studies, 97
functional disorder, 45–6
genetic association studies, 93–5
genetic linkage studies, 93
genomewide association studies (GWAS), 94–5
heritability studies, 91–3
heterogeneity within classification criteria, 71
identifying depressive subtypes, 97–8
lack of response to drug treatment, 46
multiple phenotypes hypothesis, 97
prevalence, 70
rare genetic variants approach, 96
role of trinucleotide repeats, 96
studies of inheritance patterns, 91
twin studies, 91–2
median raphe nucleus, 14
medicinal chemistry
glucocorticoid receptor antagonists, 112–14
glutamatergic targets, 108–11
melanocortin receptor antagonists, 115–16
non-monoamine based targets, 108–16
orphanin FQ/nociceptin receptor agonists, 111–12
potential multitarget approaches, 104–8
SNRIs, 103
SSRIs, 102–3
SSRIs combined with 5-HT1A receptor antagonism, 104–6
targets in the HPA axis, 112–16
tricyclic antidepressants (TCAs), 102
triple reuptake inhibitors, 106–8
vasopressin receptor antagonists, 114–15
melanocortin receptor antagonists, 115–16
milnacipran, 15, 58, 103
Minnesota Multiphasic Personality Inventory, 81
mirtazapine, 19
monoamine hypothesis of depression, 2, 13–14, 30
5-HIAA in CSF of depressed patients, 13
evidence from post-mortem brain tissue, 13
evidence from therapeutic interventions, 13–14
role of serotonin in depression, 13–14
monoamine oxidase (MAO) gene, 125
monoamine oxidase (MAO) inhibitors, 28
mood disorders
as a spectrum, 7
diagnostic challenges, 7–11
DSM-IV-TR criteria, 45
pharmacogenomics, 53
possible progressive nature, 7–11
prevalence, 45
Morris water maze test, 34
mouse
genetic models of depression, 33
transgenic models of mood disorders, 53–4
MRI (magnetic resonance imaging), 49
MRS (magnetic resonance spectroscopy)
PK/PD studies, 55
multidrug-resistance gene (MDR1), 123

National Comorbid Study (NCS), 120
n-back task, 51
nefazodone, 19
negative bias
biomarkers, 52
in depressed patients, 50–1
neuroimaging biomarkers, 50–1
preclinical animal models, 52
neuroimaging
biomarker research applications, 50
brain abnormalities in depression, 35–7
role in translational research, 46
See also translational neuroimaging

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-76058-4 - Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Edited by Chad E. Beyer and Stephen M. Stahl
Index
More information

neurokinin receptor antagonists, 7, 20
neuropsychological deficits in mood disorders
  neuroimaging biomarkers, 51–2
neuroticism endophenotype, 98
neurotransmitter receptor sensitivity hypothesis of depression, 2
neurotrophic factors, 3
neurotrophins
  role in depression, 58
NMDA receptors
  antidepressant targets, 21
nomifensine, 17
non-monoaminergic treatment approaches, 23
noradrenergic system
  and reboxetine, 16
norepinephrine (NE)
  DA/NE release stimulator (bupropion), 18
  monoamine hypothesis of depression, 2
  role in depression, 16
  selective NE reuptake inhibitors, 16–17
norepinephrine dopamine disinhibitors, 5
norepinephrine transporter (NET) blockade, 2
norepinephrine transporter (NET) gene, 125
nortriptyline, 102
novelty-induced hypophagia animal model, 34

open space swim test
  animal model of depression, 34
orosomucoid 1 and 2 (ORM1 and ORM2) genes, 123
orphanin FQ/nociceptin receptor agonists, 111–12

P38 kinase inhibitors, 23
Parkinson's disease, 96
paroxetine, 14, 20, 34, 55, 102
patient selection and stratification biomarkers, 55–6
  disease biomarkers, 56
  pharmacogenomics, 56
PDE inhibitors, 23
personalized medicine. *See* pharmacogenomics
PET (positron emission tomography), 48
  in vivo PK/PD studies, 54–5
  role in drug discovery and development, 48
  target–compound interaction biomarkers, 54
  use in preclinical animal models, 49–50
pharmacodynamic biomarkers, 54–5
pharmacodynamics, 50
  genetic basis for individual variations, 123–5
pharmacogenetics
  genetic basis for individual responses, 121–5
pharmacogenomic panels, 125
pharmacogenomics, 53
  barriers to clinical application, 125
  clinical decision-making process, 125–6
  clinical testing process, 125
  definition, 53
  genetic basis for individual responses, 121–5
  mood disorders, 53
  pilot studies of individualized medicine, 126
  potential for individualized medicine, 125
  tools for interpreting results, 125–6
  translational research applications, 53
  use in patient stratification, 56
pharmacokinetic biomarkers, 54–5
pharmacokinetics
  genetic basis for individual variations, 122–3
phMRI (pharmacological MRI), 49
pindolol, 18, 29
placebo effect
  neuroimaging, 60
preclinical animal models. *See* animal models
presymptomatic diagnosis
  neuroimaging in surrogate populations, 56–7
progression of mood disorders, 7–11
proteomics, 53
proton [^{1}H] spectroscopy, 55
psychosocial stressors
  effects of, 57–8

quetiapine, 5

radiolabeling of drugs, 54–5
reboxetine, 15, 29, 59
  and the 5-HT system, 16
  and the NE system, 16
  in combination with SSRIs, 17
  long-term efficacy, 17
  selective NE reuptake inhibitor, 16–17
  tolerability, 17
  versus SSRIs, 17
  versus TCAs, 16–17
reserpine, 14, 102
risperidone, 19

selective NE reuptake inhibitors, 16–17
sense reversal, 52
Sequenced Treatment Alternatives to Relieve Depression study. *See* STAR*D study
serotonergic system
  and reboxetine, 16
  and SSRIs, 14
serotonin
  evidence for role in depression, 13–14
  levels in post-mortem brain tissue, 13
  monoamine hypothesis of depression, 2
serotonin receptors
  1A/1B receptor targets, 18
  2A receptor gene, 125
  2A/2C receptor targets, 18–19
  2C receptor blockers, 5
  3/5A/7 receptor antagonism, 19
serotonin transporter
  blockade, 2
  effects of genetic polymorphisms, 123–4
  gene polymorphism, 53
  MDD candidate gene studies, 94

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-76058-4 - Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
Edited by Chad E. Beyer and Stephen M. Stahl
Index
More information

SERT. *See* serotonin transporter
sertraline, 102
Sigma 1 agonists, 23
smoking cessation and depression, 21
Snaith–Hamilton Pleasure scale, 76
SNRIs (selective norepinephrine reuptake inhibitors), 28–9
SNRIs (serotonin/norepinephrine reuptake inhibitors), 103
SSR/NRI combined approach, 28–9
SSRIs (selective serotonin reuptake inhibitors), 102–3
  and the serotonergic system, 14
  combined with 5-HT1A receptor antagonism, 104–6
  combined with histamine H_3 antagonist, 19
  combined with reboxetine, 17
  comparative efficacy in major depression, 14
  delayed onset of action, 14
  efficacy compared with TCAs, 14
  fluoxetine, 2
  introduction of, 28–9
  long-term efficacy, 14–15
  relapse features, 14–15
  tolerability, 14
  versus reboxetine, 17
St. John's wort, 123
staging
  major depression, 4
  unipolar depression, 4
STAR*D study, 3, 70
stress
  role in depression, 30
stress response
  animal models, 34–5
substance P
  antidepressant targeting, 20
suicide and depression, 29, 30, 120

tail suspension test
  animal model of depression, 31–3
target validation biomarkers, 52–3
target–compound interaction biomarkers, 54
TCAs (tricyclic antidepressants), 28, 102
  discovery of, 2
  efficacy compared with SSRIs, 14
  versus reboxetine, 16–17
Temperament and Character Inventory (TCI), 80
therapeutic dose range, 55
therapeutic interventions
  evidence for the monoamine hypothesis of depression, 13–14
tianeptine, 29
transgenic animal models, 53–4
translational neuroimaging, 47–50
  biomarker research applications, 50
  biomarkers of cognitive deficits, 51–2
  biomarkers of negative bias, 50–1, 52
  disease biomarkers, 50, 56
  HPA axis dysfunction under stress, 57–8
  MRS studies, 55
  patient selection and stratification biomarkers, 55–6
  pharmacodynamic biomarkers, 54–5
  pharmacogenomics applications, 53
  pharmacokinetic biomarkers, 54–5
  placebo effect, 60
  preclinical animal models, 52
  presymptomatic diagnosis in surrogate populations, 56–7
  radiolabeling of drugs, 54–5
  role of inflammation in depression, 58–9
  role of neurotrophins, 58
  target validation biomarkers, 52–3
  target–compound interaction biomarkers, 54
  therapeutic dose range, 55
  transgenic mouse models, 53–4
  vascular depression, 59–60
translational research
  aims, 46
  drug discovery and development, 46
  lack of response to drug treatment, 46
  pharmacogenomics applications, 56
  preclinical animal models, 46–7
  role of neuroimaging techniques, 46
  surrogate biomarkers, 46
trazodone
  new formulation, 4
tricyclic antidepressants. *See* TCAs
triiodothyronine, 18
trinucleotide repeats
  role in MDD, 96
triple monoamine reuptake inhibitors, 5, 15, 17–18, 106–8
tryptophan hydroxylase (TPH) gene, 125
TSNAX (Translin-associated factor X) gene, 96
twin studies
  inheritance of MDD risk, 91–2

UDP-glucuronosyltransferases (UGTs) genes, 123
unipolar depression
  distinction from bipolar disorder, 7
  staging, 4
uridine, 23

vascular depression, 59–60
vasopressin, 19
vasopressin receptor antagonists, 114–15
venlafaxine, 5, 15, 16, 29, 103, 123
vilazodone, 18

Wisconsin Card Sorting Test (WCST), 51
Wisconsin General Testing Apparatus (WGTA), 52
withdrawal of drugs of abuse
  animal models, 33
  depressive symptoms, 30

© in this web service Cambridge University Press www.cambridge.org